$BGMS

12 Health Care Stocks Moving In Friday's Intraday Session

This article highlights 12 healthcare stocks experiencing significant price movements during Friday's intraday trading session. It details both the top gainers, such as Ironwood Pharmaceuticals and Shuttle Pharmaceuticals, and the top losers, including Outlook Therapeutics and Bio Green Med Solution, along with their respective percentage changes and market capitalizations.

Original reporting
Benzinga · Benzinga Insights
Published Jan 2, 2026, 5:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jan 2, 2026, 6:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
12 Health Care Stocks Moving In Friday's Intraday Session — source image
Decision brief

The 30-second read

$BGMSNeutralLow
01

Why it matters

While specific stocks like Ironwood Pharmaceuticals and Shuttle Pharmaceuticals showed significant movement, the overall impact on the healthcare sector appears limited.

02

Market read

The intraday movements are typical for active trading days but do not suggest a significant shift in market fundamentals.

03

What to watch

Potential upcoming news or earnings reports could alter stock trajectories, but are not reflected in current data.

Timing: Limited to intraday movements, not suitable for longer-term trades.

Background

The article reports on 12 healthcare stocks with intraday price movements, highlighting top gainers and losers.

Company-level read

Ticker impact

$BGMSNeutralMedium confidence
Context

Low relevance due to minimal sentiment impact and limited price movement data.

Expected impact

Likely negligible short-term price movement.

Evidence & confidence

The sentiment score is neutral with low relevance, and no significant volume spikes suggest limited impact.

Market effects

Limited sector-wide impact expected from individual stock movements.

No significant regional market effects anticipated.

Minimal global market relevance based on current data.

Counterpoint

Some stocks may rebound or decline unexpectedly; intraday movements are not always indicative of longer-term trends.

Key entities

  • Ironwood Pharmaceuticals

    A biopharmaceutical company focused on gastrointestinal and other disorders.

  • Shuttle Pharmaceuticals

    A pharmaceutical company involved in drug development.

  • Outlook Therapeutics

    A biotech firm specializing in ophthalmic therapies.

  • Bio Green Med Solution

    A company in the green medicine sector.

Related articles

$BGMSMed

Bio Green Med Solution, Inc. (BGMS): Results of Operations and Financial Condition

Bio Green Med Solution, Inc. (BGMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BIO GREEN MED SOLUTION Reports SECOND quarter financial results and provides business update KUALA LUMPUR, MALAYSIA, August 12, 2026 – Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged primarily in the provision of fi

$BGMSHighAI 9/10

Bio Green Med Solution Surges 172 % After Announcing Deal to Acquire Malaysia Waste Tech Company - Bio Gre

Bio Green Med Solution (NASDAQ:BGMS) shares rose about 123% to $2.35 after it signed an all-stock business combination agreement with Malaysia-based Future NRG. Future NRG will become a wholly owned BGMS subsidiary; the combined firm is expected to trade on Nasdaq under BGMS, led by Datuk Dr. Doris Wong Sing Ee. The deal is expected to close in Q4 2026, pending shareholder approval and SEC registration.

$ADBEMed

A Pause on Advanced AI Is Wishful Thinking, But Adobe Stock Is a Buy Anyway

Adobe (ADBE) shares fell post-Q3 earnings despite beating estimates, citing forex headwinds. RPOs grew 8% YoY, the slowest since 2023. AI business ARR rose 150% but remains a small fraction of total ARR. New CEO Anil Chakravarthy will replace Shantanu Narayen. Analysts are mixed, with a mean target price of $269.70. The stock trades at 11x next fiscal year's EPS.